BlackRock’s Blueprint Medicines BPMC Stock Holding History

BlackRock’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,118,428	Closed	-$784M	–	5465
2025 Q2	$784M	Sell	6,118,428 -592,280	-9%	-$61.5M	0.01%	762
2025 Q1	$594M	Sell	6,710,708 -158,619	-2%	-$15.5M	0.01%	919
2024 Q4	$599M	Sell	6,869,327 -249,722	-4%	-$22.9M	0.01%	962
2024 Q3	$659M	Buy	7,119,049 +471,752	+7%	+$46.9M	0.01%	881
2024 Q2	$716M	Buy	6,647,297 +199,836	+3%	+$20M	0.02%	774
2024 Q1	$612M	Sell	6,447,461 -136,715	-2%	-$11.7M	0.01%	891
2023 Q4	$607M	Sell	6,584,176 -3,608	-0.1%	-$234K	0.02%	861
2023 Q3	$331M	Buy	6,587,784 +52,049	+0.8%	+$2.78M	0.01%	1200
2023 Q2	$413M	Sell	6,535,735 -86,568	-1%	-$4.71M	0.01%	1072
2023 Q1	$298M	Buy	6,622,303 +347,618	+6%	+$15.7M	0.01%	1271
2022 Q4	$275M	Buy	6,274,685 +518,184	+9%	+$24.9M	0.01%	1292
2022 Q3	$379M	Buy	5,756,501 +476,743	+9%	+$30.6M	0.01%	1008
2022 Q2	$267M	Sell	5,279,758 -103,380	-2%	-$6.06M	0.01%	1310
2022 Q1	$344M	Buy	5,383,138 +46,264	+0.9%	+$3.32M	0.01%	1251
2021 Q4	$572M	Buy	5,336,874 +138,860	+3%	+$14.5M	0.01%	926
2021 Q3	$534M	Buy	5,198,014 +12,096	+0.2%	+$1.13M	0.02%	928
2021 Q2	$456M	Buy	5,185,918 +145,232	+3%	+$13.3M	0.01%	1087
2021 Q1	$490M	Sell	5,040,686 -15,477	-0.3%	-$1.55M	0.01%	1022
2020 Q4	$567M	Buy	5,056,163 +268,893	+6%	+$28.3M	0.02%	809
2020 Q3	$444M	Sell	4,787,270 -149,519	-3%	-$11.5M	0.02%	814
2020 Q2	$385M	Buy	4,936,789 +246,720	+5%	+$16.7M	0.02%	874
2020 Q1	$274M	Buy	4,690,069 +432,949	+10%	+$27.9M	0.01%	937
2019 Q4	$341M	Sell	4,257,120 -41,477	-1%	-$3.11M	0.01%	1098
2019 Q3	$316M	Buy	4,298,597 +189,375	+5%	+$16.4M	0.01%	1086
2019 Q2	$388M	Buy	4,109,222 +710,147	+21%	+$58.6M	0.02%	942
2019 Q1	$272M	Sell	3,399,075 -46,916	-1%	-$3.47M	0.01%	1187
2018 Q4	$186M	Sell	3,445,991 -3,144	-0.1%	-$191K	0.01%	1380
2018 Q3	$269M	Buy	3,449,135 +127,230	+4%	+$8.84M	0.01%	1249
2018 Q2	$211M	Buy	3,321,905 +63,392	+2%	+$5.04M	0.01%	1412
2018 Q1	$299M	Buy	3,258,513 +176,652	+6%	+$15.2M	0.01%	1074
2017 Q4	$232M	Buy	3,081,861 +98,581	+3%	+$6.94M	0.01%	1253
2017 Q3	$208M	Buy	2,983,280 +119,025	+4%	+$6.36M	0.01%	1319
2017 Q2	$145M	Buy	2,864,255 +811,820	+40%	+$34.5M	0.01%	1542
2017 Q1	$82.1M	Buy	2,052,435 +2,050,457	+103,663%	+$73.4M	﹤0.01%	1908
2016 Q4	$55K	Buy	1,978 +6	+0.3%	+$181	﹤0.01%	2883
2016 Q3	$59K	Buy	1,972 +659	+50%	+$16.4K	﹤0.01%	2881
2016 Q2	$26K	Buy	1,313 +726	+124%	+$13.2K	﹤0.01%	3190
2016 Q1	$11K	Buy	587 +371	+172%	+$6.44K	﹤0.01%	3102
2015 Q4	$6K	Hold	216	–	–	﹤0.01%	3082
2015 Q3	$5K	Hold	216	–	–	﹤0.01%	2994
2015 Q2	$6K	Buy	+216	New	+$6.17K	﹤0.01%	3060

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

BlackRock's BPMC Position: Q3 2025 in Review

BlackRock sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 6,118,428 shares — an estimated $784M sold.

BlackRock first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $784M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

BlackRock reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
BlackRock sold 6,118,428 Blueprint Medicines shares in Q3 2025, an estimated $784M.
BlackRock first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
BlackRock's Blueprint Medicines position peaked at $784M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on BlackRock's 13F filing for Q3 2025, filed 12 Nov 2025.